Fluid-based biomarkers for neurodegenerative diseases

Area of Science:

• Neurology
• Biomarker Research
• Personalized Medicine

Background:

• Neurodegenerative diseases (Alzheimer's, MS, Parkinson's, ALS) are rising with aging populations.
• Fluid biomarkers from CSF, blood, and other sources can detect pathological changes early.
• These biomarkers reflect key processes like amyloid-beta deposition and tau hyperphosphorylation.

Purpose of the Study:

• To review the current state of fluid biomarkers for neurodegenerative diseases.
• To highlight advances in blood-based biomarkers and their diagnostic potential.
• To discuss challenges, ethical considerations, and future directions in the field.

Main Methods:

• Review of current literature on fluid biomarkers for neurodegenerative diseases.
• Analysis of diagnostic accuracy of various fluid biomarkers, including blood-based tests.
• Exploration of challenges such as variability, standardization, and sensitivity.

Main Results:

• Blood-based biomarkers (plasma Aβ, p-tau, TDP-43) show diagnostic accuracy comparable to CSF.
• Combining multiple biomarkers and clinical data enhances diagnostic reliability.
• Extracellular vesicles (EVs) and AI integration are emerging areas.

Conclusions:

• Fluid biomarkers are crucial for early diagnosis and monitoring of neurodegenerative diseases.
• Overcoming challenges in standardization and sensitivity is key for clinical implementation.
• Future research focusing on multi-biomarker panels and AI will advance personalized medicine.